ARTICLE | Company News
Sugen other research news
May 30, 1995 7:00 AM UTC
SUGN (Redwood City, Calif.) signed a letter of intent to enter into a CRADA with the National Cancer Institute (NCI) to further the development of SU101 as an anticancer compound. SU101 is a small mol...